Placental Growth Factor and Soluble c-Kit Receptor Dynamics Characterize the Cytokine Signature of Imatinib in Prostate Cancer and Bone Metastases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Placental Growth Factor and Soluble c-Kit Receptor Dynamics Characterize the Cytokine Signature of Imatinib in Prostate Cancer and Bone Metastases

Published:2011-07 Issue:7 Volume:31 Page:539-544
ISSN:1079-9907
Container-title:Journal of Interferon & Cytokine Research
language:en
Short-container-title:Journal of Interferon & Cytokine Research

Author:

Mathew Paul¹,Wen Sijin²,Morita Satoshi³,Thall Peter F.²

Affiliation:

1. Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

2. Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

3. Department of Biostatistics and Epidemiology, Yokahama City University Medical Center, Yokahama, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Cell Biology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.2010.0142

Reference12 articles.

1. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

2. Matrix Metalloproteinases and Angiogenic Factors

3. Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

4. Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer;Science Translational Medicine;2021-12-15

2. Imatinib;Adverse Events and Oncotargeted Kinase Inhibitors;2017

3. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer;PLoS ONE;2013-10-14

4. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor;Expert Opinion on Investigational Drugs;2013-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3